- Home
- News
- latamerica
- antigen based
Antigen Based Articles & Analysis
7 news found
The platform covers both linear and conformational epitope analysis and includes the following core services: l Binding Activity Confirmation: ELISA or Western blot assays to verify the interaction between the submitted antibody and antigen. l Glycosylation Analysis (Optional): Comparing antibody binding to glycosylated versus deglycosylated forms of the ...
Results from this study, published in BMC Medicine on May 18, entitled, Evaluation of a serum-based antigen test for tuberculosis in HIV-exposed infants: A diagnostic accuracy study, indicate that a nanoparticle-based mass spectrometry assay approach previously employed to detect adult tuberculosis (TB), also demonstrates strong TB diagnostic ...
The paper entitled “A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity” shows that Ziphius’ multi-antigenic self-amplifying RNA COVID-19 vaccine candidate induces a potent humoral and cellular immune response at low ...
Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that the Emergency Department at Box Hill Hospital in Melbourne, Australia, has initiated a 300-subject investigator-led trial using Lumos’ FebriDx® POC test to rapidly identify patients presenting with a suspected viral infection consistent with COVID-19. This study is ...
I have observed it’s no secret that there has been a significant rise in innovation in the immunotherapy area, in particular, chimeric antigen receptor (CAR) based therapies. It was exciting to be one of the earliest companies in the space. ...
The first of two manuscripts has been published in "NPJ Vaccines" and provides data demonstrating that the company’s structure-guided antigen design and synthetic nanoparticle delivery platform has been used to generate a candidate vaccine (V-306) for prophylaxis against RSV infection. ...
CARB-X is awarding Vaxdyn, based in Seville, Spain, up to US$892,000, plus an additional $6.36 million if certain project milestones are met, to develop a new vaccine to prevent life-threatening drug-resistant infections, including pneumonia. ...